Breaking through the barriers against next-generation cancer diagnostics

Early and accurate cancer detection remains one of the greatest unsolved challenges in global healthcare. Despite major advances in genomics, proteomics and liquid biopsy, the path to next-generation cancer diagnostics is blocked by technical, regulatory and economic barriers — leaving too many diagnoses too late for effective treatment.

This report outlines a new, UK-led mechanism to overcome these barriers through the Next-generation Cancer Diagnostics Programme (NG-Dx) for the global industry, using public-private partnerships to accelerate innovation and translation of cancer diagnostics based on multi-omics.

Building on the three foundational pillars of ctDNA, proteomics, and spatial biology, the report details how programmes like NG-Dx could unite the global industry, innovative emerging companies, academia, government and the NHS to deliver fully integrated, clinically actionable next-generation diagnostics. It sets out the underlying clinical needs, a technical roadmap of solutions, and partnership model required to bridge the global innovation gap, standardise workflows, and develop scalable, cost-effective solutions that can detect cancer earlier and guide more precise treatment..

Download the report to explore how collaboration can unlock the next generation of cancer diagnostics, and transform outcomes for patients worldwide.